Acute Repetitive Seizures Market 2018| New Business Opportunities and Research

The global acute repetitive seizures market size is expected to reach USD 3.19 billion by 2025, according to a new report by Grand View Research, Inc. The report also states that the market will expand at a strong CAGR of 47.8% during the forecast period. Rise in the number of initiatives to increase the awareness about epilepsy is the major factor driving the market.

The market is currently led by generic drugs which mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only approved drug for use in U.S. and buccal midazolam in European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and progesterone are majorly used off label. The market is expected to be consolidated with few major companies and high market share.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market.

There are several routes of drug administration; out of which, nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/acute-repetitive-seizures-market

Further key findings from the study suggest:

• Global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period
• Diastat rectal gel was the dominant product segment in 2017 due to efficacy of the route of administration and affordability of the product
• USL-261 is expected to witness a lucrative CAGR over the forecast period. USL-21 has an edge over the other drugs owing to its superior clinical profile and positive phase III results
• North America held the largest share in 2017 due to factors, such as growing initiatives for raising awareness about epilepsy and seizures
• Germany is anticipated to witness lucrative growth over the next decade owing to technological advancements in scientific, clinical, and medical fields
• Some of the key companies in the market are UCB S.A.; Neurelis, Inc.; and Alexza Pharmaceuticals, Inc. These companies are likely to dominate the market and gain maximum share over the forecast period

Arrhythmia Monitoring Devices Market Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2025

The global arrhythmia monitoring devices market size is expected to reach USD 8.41 billion in 2025 with a CAGR of 6.8% during the forecast period, according to a new report by Grand View Research, Inc. Continuous R&D activities in the field of cardiac monitoring are leading to technological expansion. This, in turn, is positively influencing the growth of the arrhythmia monitoring devices market. Wearable diagnostic patch by iRhythm Technologies, Inc., Zio, has led to symptomatic arrhythmia monitoring, which is superior in comparison to conventional Holter monitors.

Big pharma and medical device companies are heavily investing in R&D to perform a detailed mapping of cardiac arrhythmia. In February 2018, Medtronic received FDA clearance for the first non-invasive cardiac mapping system, CardioInsight. It includes wearable 252-electrode sensor vest that creates 3D electroanatomic maps of heart by combining data from a cardiac computed tomography scan with ECG signals collected from the chest region.

In addition to these technologies, emergence and advancements in mobile cardiac telemetry are leading to further progress of the overall market. In October 2017, Abbott received FDA clearance for Confirm Rx, a smartphone-compatible implantable cardiac monitor indicated for arrhythmia diagnosis. Boston Scientific announced its FDA approval for Resonate, a line of cardiac resynchronization therapy defibrillator and cardioverter defibrillator systems for the cardiac management.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/arrhythmia-monitoring-devices-market

Further key findings from the report suggest:

• The arrhythmia monitoring devices market is highly competitive and is rapidly evolving with numerous potential market players
• Holter monitors dominated the market in terms of revenue in 2017. On the other hand, mobile cardiac telemetry is expected to witness the fastest growth rate during the forecast period
• Atrial fibrillation dominated the market in terms of revenue in 2017. The growth in the number of untreated cases of arrhythmias are leading to increasing need for advanced cardiac monitoring devices
• Heightened adoption of sophisticated technologies has led to the expansion of the market. Kardia Mobile by AliveCor captures ECG in 30 seconds projecting the heart rhythm for conditions such as atrial fibrillation
• The hospitals and clinics segment held the largest share in the market in 2017. On the other hand, diagnostic centers are likely to experience the fastest growth over the forecast period
• North America commanded the leading share in the market in 2017 due to faster regulatory approvals for innovative devices and procedures
• AliveCor, Inc.; Applied Cardiac Systems; BioTelemetry, Inc.; BIOTRONIK; Fukuda Denshi Co., Ltd.; GE Healthcare; iRhythm; Medi-Lynx; St. Jude Medical (Abbott); Medtronic; Nihon Kohden Corporation; Nuubo; and Spacelabs Healthcare are some of the key players operating in this market.

Veterinary Anesthesia Equipment Market 2019 | Global Trends, Market Share, Industry Size, Growth, Opportunities and Forecast to 2025

The global veterinary anesthesia equipment market size is expected to reach USD 1.66 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.2% during the forecast period. Increasing incidence of oral diseases in dogs & cats is creating a greater need for veterinary machines for dental surgery. This, in turn, is providing numerous opportunities to the manufactures operating in the veterinary anesthesia machines market space. In addition, rising incidence of foodborne & zoonotic diseases and bacterial infections that lead to critical conditions are anticipated to fuel the demand over the forecast period. The veterinary medicine field experienced drastic technological developments in the last 20 years.

Growing number of animal health practitioners in response to advanced anesthesiology is expected to augment the demand during the forecast period. In addition, rising penetration of pet insurance is anticipated to fuel the adoption of surgical practices for animals, which will thereby boost the growth of the veterinary anesthesia equipment market. Furthermore, increasing number of pet owners is anticipated to promote the adoption of animal health care services, which is likely to drive the overall market during the forecast period.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/veterinary-anesthesia-machines-market

Further key findings from the report suggest:

• The complete veterinary anesthesia equipment segment accounted for the largest revenue share in 2017. The demand for integrated systems by animal health practitioners in surgical procedures is projected to increase over the forecast period
• The small animal segment, which includes companion animals, is anticipated to witness significant growth in the coming years due to growing pet adoption and increasing concerns regarding pet health by owners.
• Clinics & hospitals are expected to witness substantial growth during the forecast period due to increasing pet owner’s preference and availability of surgeons in these facilities
• Presence of a large number of established animal health clinics and laboratories that are consistently striving for extensive commercialization of their services in North America is bolstering the growth of the regional market
• Asia Pacific is poised to experience lucrative growth in the coming years owing to increasing collaborations by public and private organizations to promote the adoption of animal health services
• Some of the key companies present in the market are Mindmark, JD Medical, Smiths Medical, and Patterson Companies. The companies are involved in development of novel analgesic that gives relief to pets. There are various molecules in pipeline expecting approval during the forecast period.

Sinus Dilation Devices Market 2018| Future Trends And Forecast By 2025

The global sinus dilation devices market size is expected to reach USD 3.6 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.9% during the forecast period. The market is driven by rising prevalence of chronic sinusitis. Moreover, increasing adoption of minimally invasive procedures owing to favourable reimbursement scenario is projected to augment the market growth. For instance, according to the Centers for Disease Control and Prevention in 2017, 26.9 million adults in U.S. were diagnosed with sinusitis, which was around 11.0% of the adult American population then.

North America was the dominant regional market for sinus dilation devices in 2017. The growth of this region was mainly due to the presence of a large number of key companies. Technological developments pertaining to sinus dilation devices by leading companies is expected to augment the North America and Europe market growth. In addition, mergers and acquisitions, new product development, and geographical expansion are other key strategies adopted by companies to increase their market penetration. For instance, in June 2015, Entellus Medical, Inc. launched XprESS LoProfile Multi-Sinus Dilation System in Europe. These surgical tools were equipped with multi-functional system, which combined balloon dilation with irrigation, suction, and image guidance.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/sinus-dilation-devices-market

Further key findings from the report suggest:

• Balloon sinus dilation devices held the largest share in the past due to their greater acceptance and advancements in sinus surgical procedures
• Standalone procedures held major share of the global sinus dilation devices market in 2017 owing to the higher success rate of revision surgeries
• The hospitals end-use segment held the major share of the market in 2017
• Asia Pacific is likely to exhibit the fastest growth during the forecast period owing to increasing awareness about surgical procedures of sinus
• Increased disposable income, presence of target population, and improving healthcare infrastructure, and improvement in patient are also estimated to drive the regional market
• Few of the key companies in the market include Medtronic PLC; Smith & Nephew PLC; Acclarent, Inc.; Intersect ENT, Inc.; Entellus Medical, Inc.; Olympus Corporation; and SinuSys Corporation.

Biomaterials Market Trends, Estimates and Forecast Report | 2018-2025

The global biomaterial market size is expected to reach USD 250.4 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 14.7% during the forecast period. Technological innovations in the field of biomaterials are leading to development of advanced products, which in turn is working in favor of the market. Widening base of geriatric population worldwide and subsequent rise in prevalence of cardiovascular and orthopedic disorders are providing a fillip to the market.

Biomaterials are now widely used in healthcare fields such as cardiovascular, orthopedic, dental, plastic medical procedure, wound repair, ophthalmology and neurological conditions. Furthermore, they are utilized in different advanced healthcare technologies such as cosmetic surgeries, tissue engineering, medical implants, and advanced drug delivery.

Geographically, North America held the largest share in the biomaterials market in 2017. The growth of the regional market can be attributed to various technological and mechanical progressions, high utility of medical services, growing geriatric population, and higher medical insurance coverage.

Some of the prominent companies operating in the market are DSM; BASF SE; Evonik Industries AG.; Berkeley Advanced Biomaterials, Inc.; CAM Bioceramics BV; Carpenter Technology Corporation; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; Covalon Technologies Ltd.; Collagen Matrix, Inc.; Medtronic, Inc.; Purac Biomaterials; Ticona GmbH; Osteotech, Inc.; and Bayer AG.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/biomaterials-industry

Further key findings from the report suggest:

• Rapid advancements in the field of genetics and increasing usage of biomaterials in oncology, personal genomics, and agrigenomics are expected to drive the market
• Factors such as high cost of instruments and platforms, ethical concerns, and ambiguous reimbursement policies in some countries are estimated to negatively impact the growth of the market
• Based on products, the natural segment is anticipated to register the highest CAGR of close to 16.7% during the forecast period
• On the basis of application, orthopedics was the most prominent segment in 2017, accounting for more than 20.0% of the market revenue
• There are many industrial scale healthcare projects and genome research projects launched in North American & European countries for improving the adoption of advanced healthcare technologies
• Strong presence of a raft of biomaterial technology providers, better infrastructure, patient awareness, and good healthcare facilities in these regions are aiding market growth.

Disposable Endoscopes Market Sales, Segments, Capacity Outlook, Growth, Potential Applications and Analysis by 2025

The global disposable endoscopes market size is expected to reach USD 2.75 billion by 2025 and is expected to expand at a CAGR of 26.9% over the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of nosocomial infections due to contaminated endoscopes is a major factor driving demand for disposable endoscopes. Recent developments in disposable endoscopes, particularly bronchoscopes and colonoscopies, are also expected to positively impact market growth over the next few years.

Growing need for cost reduction in endoscopy procedures propels demand for disposable endoscopes as these are more cost effective than reusable ones. High cost of reprocessing procedures used for reusable endoscopes is further expected to drive the market. Failure of current reprocessing procedures and non-compliance of reprocessing guidelines is further expected to boost adoption and acceptance levels of disposable endoscopes.

Recent technological advancements have spurred demand for disposable endoscopes in hospitals, diagnostic centers, and clinics for a number of applications. They are used in several specialties, including ENT, laparoscopy, gynecology, arthroscopy, gastroenterology, urology, and proctoscopy.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/disposable-endoscopes-market

Further key findings from the report suggest:

• By application, bronchoscopy emerged as the largest segment in terms of revenue in 2017 owing to increased device availability and technological advancements
• On the basis of end use, hospitals accounted for the largest revenue share in 2017 owing to rising incidence of hospital acquired infections related to contaminated endoscopes
• In terms of geography, North America accounted for the largest revenue share in 2017 and Asia Pacific is expected to grow at a lucrative rate over the forecast period
• Ambu A/S, Boston Scientific Corporation, and OBP Medical Corporation are some of the major players operating in the market.

Hospital Gowns Market Survey, Product Cost, and Research Report 2018-2025

The global hospital gowns market size is expected to reach USD 3.87 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 6.3% during the forecast period. Increasing number of surgeries, several initiatives pertaining to hospital gowns taken by major players, and rising incidence of hospital-acquired infections (HAIs) are among the key factors projected to drive the market.

Rising number of surgeries globally is also poised to provide an upthrust to the market during the forecast period. For instance, as per Mölnlycke Health Care AB, 70 million surgical procedures are performed every year in Europe. The trend is creating a significant increase in the demand for hospital gowns as they are one of the essential requirements for surgical procedures. Furthermore, according to the Healthcare Cost and Utilization Project (HCUP), in 2014, around 9,942,000 surgeries were performed in U.S. ambulatory setting. Patient gowns provide protection against hospital-acquired infections to some extent owing to which surgeons recommend these gowns.

Key players are also taking initiatives to modify and redesign hospital gowns with an aim to improve the comfort level of patients. For instance, Medstar made a collaboration with New York health wear company, Care+Wear, where students of New York's Parsons School of Design have designed innovative patient gowns. These gowns have been put to test run in hospitals by the company in order to get quality assurance and based on that the product will be launched officially. Hence, such initiatives are likely to propel the market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/hospital-gowns-market

Further key findings from the report suggest:

• In terms of revenue, surgical gowns are anticipated to register the highest CAGR during the forecast period. Rising number of surgeries worldwide and increasing cases of hospital-acquired infections are contributing to the growth of the segment
• By 2025, Asia Pacific is estimated to witness the fastest CAGR over the forecast period. Penetration of major players in untapped areas of this region is likely to stimulate the growth of the regional market
• Some of the key companies present in the market are Medline Industries, Inc.; Standard Textile Co., Inc.; Angelica Corporation; AmeriPride Services Inc.; and Cardinal Health.

Flexible and Semi-rigid Ureteroscopy Market Worth USD 1.12 Billion By 2025

The global flexible & semi-rigid ureteroscopy market size is expected to reach USD 1.12 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 5.1% over the forecast period. Increasing incidence of urolithiasis coupled with growing geriatric and obese population is likely to drive the market. Furthermore, introduction of technologically advanced products is also projected to drive the growth.

According to the U.S. Department of Commerce, in 2015, the world population was 7.3 billion, out of which around 8.5% or 617.1 million people were aged 65 years and more. The rapid increase in elderly population is likely to drive growth of the market for flexible and semi-rigid ureteroscopy over the forecast period.

Ureteroscopy is an ideal and safe choice for treating ureteral stones, tumors or strictures. Introduction of technologically advanced products in terms of size and design has allowed ureteroscopes to easily access ureter and kidney, eliminating the need for any surgical incision. Also, with semi-rigid and flexible ureteroscopes; almost all parts of urinary tract can be easily assessed, with high quality digital optics enabling accurate assessment of mucosal lesions and stones.

Introduction of technologically advanced products such as single-use ureteroscopes is driving the market. For instance, Boston Scientific launched LithoVue, a new single-use digital ureteroscope, in U.S. and Europe. It provides high-quality digital visualization and seamless navigation for constant clinical performance during each procedure. Flexible ureteroscopes was the largest product segment in 2017 and is likely to witness fastest growth over the forecast period. The wide usage of these products is attributed to their accuracy and cost effectiveness.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/flexible-semi-rigid-ureteroscopy-market

Further key findings from the report suggest:

• The urolithiasis segment is expected to hold largest market share, mainly due to the high prevalence of kidney stone
• Hospitals was the largest segment of the flexible and semi-rigid ureteroscopy in 2017 as majority of diagnostic tests are performed in hospitals, mainly due to easy access
• Ambulatory surgical centers segment is expected to witness significant growth over the forecast period. As the payers and government analyze costs and shift towards value-based care, outpatient surgery is likely to witness a rise
• North America was the largest revenue generating region in 2017, followed by Europe. North America is the most well-established region in terms of usage of ureteroscopes and makes up most of the existing market
• Asia Pacific is likely to witness the fastest growth over the forecast period due to unmet clinical needs and requirement for better diagnosis. Growing government initiatives and clinical research activities for advanced diagnostics are expected to further propel the regional growth
• The players operating in this space are Boston Scientific, Olympus, Karl Storz Medical AG, Stryker, Elmed Medical Systems, Maxer Endoscopy, Richard Wolf, and Vimex Endoscopy. Most companies adopt strategies such as geographic expansion, business collaborations, and introducing technologically advanced products to increase their market share.

Herbal Supplements Market Share of Major Challenges, Demand & Analysis to 2025

The global herbal supplements market size is expected to reach USD 8.5 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 6.2% over the forecast period (from 2018 to 2025). Growing geriatric population and awareness regarding preventive healthcare are expected to be the key factors driving the market. Rising healthcare expenditure is also likely to augment the market growth. Easy availability of herbal supplements owing to various strategies, such as direct selling and bundled offerings, adopted by companies will also support market growth.

Increasing awareness regarding the benefits associated with the consumption of herbal supplements is also likely to have a positive impact on the product demand. Manufacturers are focusing on product placement strategies to increase their sale across all consumer groups. For instance, the advertisements targeting children segment are focused on endorsing the use of supplements for nutritional values for healthy growth. According to the article cited by NCBI in 2013, nearly 80% of the global population relies on herbal supplements as part of primary healthcare. Thus, increasing acceptance of natural therapies and products is also propelling the market growth.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/herbal-supplements-market

Further key findings from the study suggest:

• Echinacea supplements segment accounted for the largest revenue share in 2017 owing to high adoption of these supplements for infection prevention
• Turmeric supplements segment is expected to emerge with the fastest CAGR 8.1% over the forecast period owing to the rising clinical studies demonstrating the therapeutic benefits of these supplements
• Capsule segment accounted for the largest revenue share in 2017 owing to the large number of products available in capsule form
• Adult segment emerged as the largest consumer group in the past while pregnant women segment is expected to emerge with the fastest CAGR 7.0% over the forecast period
• Asia Pacific was the largest regional market; however, Europe is anticipated to witness the fastest CAGR of 8.2% over the forecast period
• Jarrow Formulas, Inc.; Solgar, Inc.; Nature’s Bounty; Ancient GreenFields Pvt. Ltd.; Gaia Herbs; and Now Foods are some of the key companies in the herbal supplements market

Cancer Immunotherapy Drug Discovery Outsourcing Market Worth USD 1.7 Billion by 2025

The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-drug-discovery-outsourcing-market

Further Key Findings From the Report Suggest:

• Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy
• Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development
• North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
• Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

Connected Drug Delivery Devices Market Worth USD 717.7 Million By 2025

The global connected drug delivery devices market size is expected to reach USD 717.7 million by 2025, according to a new report by Grand View Research, Inc. The market is projected to expand at a strong CAGR of 25.1% during the forecast period. Factors contributing to the growth of this market include rise in awareness regarding adverse effects of non-adherence to medication and increased adoption of IoT, patient connectivity, and engagement. Based on the product type, connected drug delivery systems are categorized as sensors and integrated devices.

The sensors segment accounted for the largest market share of 72.6% in 2017. The connected sensors are cost-effective as compared to their integrated counterparts. Moreover, the cost of switching from a conventional systems to add-on sensors is low. The integrated systems are anticipated to witness the fastest CAGR over the forecast period owing to reduced prices of these devices. These devices also provide more detailed insights regarding the dosage and patient’s compliance and health records, which is expected to drive their demand further.

North America held the largest revenue share at 34.4% and will continue to retain its leading position over the forecast period. Quick adoption of advanced devices and technologies and high per capita healthcare expenditure are expected to boost the demand for connected drug delivery systems in the region. Some of the key companies in the global connected drug delivery device market include Propeller Health; Proteus Digital Health, Inc.; Adherium Limited; BIOCORP; and Merck KGaA.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/connected-drug-delivery-devices-market

Further key findings from the study suggest:

• The connected sensors segment led the market in terms of revenue share in 2017. Cost-effectiveness and easy availability of these sensors were the major factors behind the segment growth
• The Bluetooth technology was the largest technology segment in 2017 and accounted for 70.5% of the global market share
• The homecare segment is anticipated to witness the fastest CAGR of 26.9% owing to increasing shifting preference for homecare settings or Point of Contact (PoC)
• North America led the market in 2017 owing to the presence of a large number of early adopters and high per capita healthcare expenditure
• Some of the key companies in the global connected drug delivery devices market are Propeller Health, Proteus Digital Health, Adherium Ltd., BIOCORP, and Merck KGaA.